TABLE 2.

Genotype at baseline and PDVF in participants with INSTI resistance-associated substitutions^a

Patient	Wk of PDVFb	Integrase			Protease		Reverse transcriptase
		Baseline	PDVFc	Fold change in dolutegravir sensitivityd	Baseline	PDVFb	Baseline	PDVFc
1	32	L74L/M	R263K/R e	1.1f	I84I/V
2	168		L74M, G118R	25.1			M41L, T215L	M41L, T215F/L
3	40	V151I	G118R, E138E/K, V151I	5.9			K103S, V106I/V, V179I/V, M184M/V, G190A, Y318F	K103S, M184V, G190A
4	24		E92E/Q, G118G/R	NA			T69A/D/N/T	M184V
5	24	L74I	L74I, G118R	9.6g			M184V, H221Y	M184V, H221Y
6	24	L74I	T66I, L74I, G118R	19.3	K20R	K20R	V179I, M184V, K238R	V179I, M184V, K238R
7	192	NA	E157Q	NA			V179I	V179I
8	24	NA	L74I	NA	L10I/L, K20K/R, L33F, M46I, I50V, I54V, T74P, V82A	L10I/L, K20K/R, L33F/L, M46I/M, I50I/V, I54I/V, T74P/T, V82A/V	M41L, D67N, T69N/T, K70R, L74I, A98G, M184V, T215F, K219Q, K238R	M41L/M, D67D/N, T69N/T, K70K/R, L74I/L, A98A/G, M184M/V, T215F/I/S/T, K219Q, M230I/M, K238R

^aINSTI, integrase strand transfer inhibitor; NA, not available; PDVF, protocol-defined virologic failure.

^bTesting for resistance took place at the next available time point after PDVF for participant 1 (week 36), participant 2 (week 192), and participant 3 (week 52).

^cTreatment-emergent substitutions are in bold.

^dFold change in dolutegravir susceptibility at study visits after meeting PDVF criteria except where noted. The clinical cutoff for dolutegravir is 4.0.

^eGenotypes at weeks 136 and 168 were E138A/E/K/T, S147G/S, and R263K and E138T, S147G, and R263K, respectively.

^fThe fold change in dolutegravir susceptibility at weeks 136 and 168 was 5.0 and 5.1, respectively. The fold change in dolutegravir susceptibility at baseline was 1.04.

^gThe fold change in dolutegravir susceptibility at baseline was 0.62.